Whitehawk Therapeutics (NASDAQ:WHWK) Releases Earnings Results, Beats Expectations By $0.04 EPS

Whitehawk Therapeutics (NASDAQ:WHWK) issued its quarterly earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.04, FiscalAI reports.

Whitehawk Therapeutics Stock Down 5.1%

Shares of WHWK traded down $0.21 during trading hours on Thursday, hitting $3.94. The company had a trading volume of 136,407 shares, compared to its average volume of 208,642. The firm has a market cap of $194.75 million, a P/E ratio of 8.38 and a beta of 0.70. The stock’s 50 day moving average price is $3.75 and its 200 day moving average price is $2.96. Whitehawk Therapeutics has a 52-week low of $1.55 and a 52-week high of $4.48.

Analysts Set New Price Targets

A number of analysts have recently issued reports on WHWK shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. Citigroup started coverage on Whitehawk Therapeutics in a research report on Thursday, April 16th. They set an “outperform” rating for the company. Wall Street Zen downgraded Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Oppenheimer initiated coverage on Whitehawk Therapeutics in a research report on Thursday, February 5th. They set an “outperform” rating and a $6.00 price target on the stock. Finally, Citizens Jmp initiated coverage on Whitehawk Therapeutics in a research report on Thursday, April 16th. They set a “market outperform” rating and a $8.00 price target on the stock. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $7.00.

Insider Transactions at Whitehawk Therapeutics

In other news, CEO David James Lennon sold 102,395 shares of Whitehawk Therapeutics stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $3.51, for a total value of $359,406.45. Following the transaction, the chief executive officer owned 691,154 shares in the company, valued at approximately $2,425,950.54. The trade was a 12.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Bryan Ball sold 92,460 shares of Whitehawk Therapeutics stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $3.64, for a total value of $336,554.40. Following the completion of the transaction, the insider owned 397,106 shares in the company, valued at approximately $1,445,465.84. This represents a 18.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 705,358 shares of company stock worth $2,584,564. Company insiders own 49.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. KVP Capital Advisors LP purchased a new position in shares of Whitehawk Therapeutics in the fourth quarter worth about $5,242,000. Quadrature Capital Ltd purchased a new position in shares of Whitehawk Therapeutics in the fourth quarter worth about $28,000. Eversept Partners LP purchased a new stake in shares of Whitehawk Therapeutics during the fourth quarter worth about $630,000. ADAR1 Capital Management LLC purchased a new stake in shares of Whitehawk Therapeutics during the fourth quarter worth about $188,000. Finally, Marshall Wace LLP bought a new stake in shares of Whitehawk Therapeutics in the fourth quarter worth about $164,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.